Canadian Institutes of Health Research (CIHR) Team in Aboriginal Antidiabetic Medicines, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, QC, Canada H3C 3J7 ; Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, QC, Canada H3C 3J7 ; Institute of Nutrition and Functional Foods, Université Laval, Quebec City, QC, Canada G1V 0A6 ; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada H1W 4A4.
Evid Based Complement Alternat Med. 2013;2013:172537. doi: 10.1155/2013/172537. Epub 2013 May 27.
Populus balsamifera L. (BP) is a medicinal plant stemming from the traditional pharmacopoeia of the Cree of Eeyou Istchee (CEI-Northern Quebec). In vitro screening studies revealed that it strongly inhibited adipogenesis in 3T3-L1 adipocytes, suggesting potential antiobesity activity. Salicortin was identified, through bioassay-guided fractionation, as the active component responsible for BP's activity. The present study aimed to assess the potential of BP and salicortin at reducing obesity and features of the metabolic syndrome, in diet-induced obese C57Bl/6 mice. Mice were subjected to high fat diet (HFD) for sixteen weeks, with BP (125 or 250 mg/kg) or salicortin (12.5 mg/kg) introduced in the HFD for the last eight of the sixteen weeks. BP and salicortin effectively reduced whole body and retroperitoneal fat pad weights, as well as hepatic triglyceride accumulation. Glycemia, insulinemia, leptin, and adiponectin levels were also improved. This was accompanied by a small yet significant reduction in food intake in animals treated with BP. BP and salicortin (slightly) also modulated key components in signaling pathways involved with glucose regulation and lipid oxidation in the liver, muscle, and adipose tissue. These results confirm the validity of the CEI pharmacopoeia as alternative and complementary antiobesity and antidiabetic therapies.
银白杨 L.（BP）是一种药用植物，源自 Eeyou Istchee（魁北克北部的 Cree）的传统药典。体外筛选研究表明，它强烈抑制 3T3-L1 脂肪细胞的脂肪生成，表明具有潜在的抗肥胖活性。通过生物测定指导的馏分分离，鉴定出柳皮苷是 BP 活性的活性成分。本研究旨在评估 BP 和柳皮苷在减少肥胖和代谢综合征特征方面的潜力，在饮食诱导肥胖的 C57Bl/6 小鼠中。小鼠接受高脂肪饮食（HFD）十六周，在最后八周的 HFD 中引入 BP（125 或 250mg/kg）或柳皮苷（12.5mg/kg）。BP 和柳皮苷有效降低了全身和腹膜后脂肪垫的重量，以及肝甘油三酯的积累。血糖、胰岛素、瘦素和脂联素水平也得到改善。这伴随着用 BP 治疗的动物的食物摄入量略有但显著减少。BP 和柳皮苷（略有）还调节了与肝脏、肌肉和脂肪组织中葡萄糖调节和脂质氧化相关的信号通路中的关键成分。这些结果证实了 CEI 药典作为替代和补充性抗肥胖和抗糖尿病疗法的有效性。
